Business Wire

City of Vienna Earns IEEE AI Ethics Certification Mark; Reinforcing Commitment to Digital Humanism Strategy

15.11.2021 18:30:00 EET | Business Wire | Press release

Share

IEEE, the world's largest technical professional organization dedicated to advancing technology for humanity, and the IEEE Standards Association (IEEE SA) today announced that the City of Vienna has become the first city worldwide to earn the IEEE CertifiAIEd AI Ethics (AIE) Certification Mark to advance the city’s Digital Humanism strategy.

"With artificial intelligence, we can make many tasks in administration more efficient and faster. As the City of Vienna, we are taking on a pioneering role here," says Peter Hanke, City Councillor for Economic Affairs. "Particularly in direct contact with people and especially in dealing with data, caution is required. People are at the center of our considerations."

The IEEE CertifAIEd mark recognizes that a product, service, or system has been verified to meet relevant ethical criteria, contributing towards a greater level of confidence and demonstrating a proactive approach to building public trust in AI systems. There are currently four sets of criteria available for IEEE CertifiAIEd certification:

  • Transparency criteria relate to values embedded in a system design, and the openness and disclosure of choices made for development and operation.
  • Accountability criteria recognize that the system/service autonomy and learning capacities are the results of algorithms and computational processes designed by humans and organizations that remain responsible for their outcomes.
  • Algorithmic bias criteria relate to the prevention of systematic errors and repeatable undesirable behaviors that create unfair outcomes.
  • Privacy criteria are aimed at respecting the private sphere of life and public identity of an individual, group, or community, upholding dignity.

“IEEE has laid the groundwork for AI Ethics based on principles and standards created by hundreds of our volunteers over the past five years, which are already having a global impact,” said Konstantinos Karachalios, Managing Director of IEEE SA. “IEEE CertifAIEd represents our continued evolution of the AI Ethics ecosystem by establishing a program to inspire trust and a means towards responsible implementation of AI systems that demonstrates an organization’s commitment to upholding human values, dignity, and well-being, and to respecting, protecting and preserving fundamental human rights. We are honored to work with the City of Vienna to support their Digital Humanism platform and to provide the mark for responsible innovation required in today’s world to inspire certified trust for their AI Systems.”

IEEE’s CertifAIEd program aims to enhance confidence in public and private enterprises that realize the benefits of AI ethics by earning certification in the absence of or as a complement to broadly accepted and enforced regulations for AI. As proposed legislation in the EU would require conformity certification for any AI based systems to mitigate any unintended risks, the City of Vienna is addressing these risks and demonstrating the benefits of responsible government innovation by earning the IEEE CertifAIEd mark. In doing so, it sets a precedent for other cities and entities to achieve their aims in a responsible and human-centric manner.

"Data security and data protection must be at the forefront when using AI from the very beginning. That's why we relied on international expertise during the development of the software and had our program ethically certified," said Deputy Director General, Peter Weinelt.

Cities, entities, and individuals interested in learning more about the criteria or getting involved in the program can visit the IEEE CertifAIEd website.

To learn more about IEEE SA or about any of its many market-driven initiatives, visit us on Facebook, follow us on Twitter, connect with us on LinkedIn, or on the Beyond Standards Blog.

About the IEEE Standards Association

IEEE Standards Association (IEEE SA) is a collaborative organization where innovators raise the world's standards for technology. IEEE SA provides a globally open, consensus-building environment and platform that empowers people to work together in the development of leading-edge, market-relevant technology standards, and industry solutions shaping a better, safer and sustainable world. For more information, visit https://standards.ieee.org.

About IEEE

IEEE is the world’s largest technical professional organization dedicated to advancing technology for the benefit of humanity. Through its highly cited publications, conferences, technology standards, and professional and educational activities, IEEE is the trusted voice in a wide variety of areas ranging from aerospace systems, computers, and telecommunications to biomedical engineering, electric power, and consumer electronics. Learn more at https://www.ieee.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Tania Olabi-Colon, Director, Brand Marketing & Communications

Olivia Wang, Marketing & Communications Manager
standards-pr@ieee.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye